About 100 reports

  • Blood Disease Drugs Sales Volume
  • Blood Disease Drugs Industry Structure
  • Blood Disease
  • Pharmaceutical
  • China
  • Demand
  • Eisai Co., Ltd.
  • Blood Disease Drugs Sales Volume
  • Other Blood Disease Drugs
  • Blood Disease
  • China
  • Demand
  • Market Size
  • Shanghai Schering-Plough Pharmaceutical Company, Ltd
  • Blood Disease Drugs Sales Volume
  • Blood Disease Drugs Imports
  • Blood Disease
  • China
  • Trade
  • Lijun Pharmaceutical Co., Ltd.
  • Shanghai Schering-Plough Pharmaceutical Company, Ltd

The report features 2017 current and 2018 forecast estimates on the sales of Patient care - Blood diseases sold through Offices of physicians nationally and for all ## U. S.

  • Blood Disease
  • Pathology
  • United States
  • Demand

The report features 2017 current and 2018 forecast estimates on the sales of Patient care - Blood diseases sold through Medical & surgical hospitals nationally and for all ## U. S.

  • Blood Disease
  • Pathology
  • United States
  • Demand
  • Global Acquired Orphan Blood Diseases Therapeutics Market
  • Global Acquired Orphan Blood Diseases Therapeutics Market
  • Blood Disease
  • Alexion Pharmaceuticals, Inc.
  • Amgen Inc.
  • Celgene Corporation
  • F. Hoffmann-La Roche Ltd.
  • May 06, 2016: Drug-like Compound Shows Promise in Treating Two Blood Diseases
  • M-009 - DRUG PROFILE
  • Blood Disease
  • Pathology
  • Therapy
  • United States
  • Product Initiative
  • May 06, 2016: Drug-like Compound Shows Promise in Treating Two Blood Diseases
  • The content of this press release is solely the views of its authors and does not represent the official views of the National Institutes of Health.
  • Blood Disease
  • Pathology
  • Therapy
  • United States
  • Product Initiative
  • May 06, 2016: Drug-like Compound Shows Promise in Treating Two Blood Diseases
  • M-009 - Drug Profile
  • Blood Disease
  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative
  • Current Ongoing Trials for Rare Blood Diseases
  • 4.1.4 Development of Drugs for Rare Blood Diseases
  • Blood Disease
  • United States
  • World
  • Demand
  • Celgene Corporation

Many diseases discussed in this report are global issues, and a need exists for newer diagnostic and treatment strategies.

  • Blood Disease
  • Cancer
  • Pathology
  • United States
  • World
  • Fanconi Anemia - Drug Profiles
  • Fanconi Anemia - Companies Involved in Therapeutics Development
  • Blood Disease
  • Pathology
  • Therapy
  • United States
  • Product Initiative

Genetic blood diseases (n=##) include SCID (Severe Combined Immune Deficiency) (n=##), thalassemia major (n=##), Wiskott-Aldrich syndrome (n=##), sickle cell disease (n=##), and several others.

  • Blood Disease
  • Pharmaceutical
  • United States
  • Company
  • Bellicum Pharmaceuticals, Inc.

About GBT## in Sickle Cell Disease Product Approvals Sep ##, 2017: Global Blood Therapeutics Receives Rare Pediatric Disease Designation from FDA for GBT## for Treatment of Sickle Cell Disease Global Blood Therapeutics, Inc. announced that the U. S.

  • Blood Disease
  • Pharmaceutical
  • Therapy
  • World
  • GlobalData's company
  • Hematology Drugs Market Historic Growth

Hematology drugs market offers drugs, blood and blood products that are used for the treatment of diseases such as rare genetic disorders, anemia, and conditions related to sickle cell disease and other related diseases.

  • Blood Disease
  • World
  • Bayer AG
  • Daiichi Sankyo Company
  • Shire plc
  • BIOSIMILARS MARKET SIZE FOR BLOOD DISORDERS, BY REGION, 2014-2021 (USD MILLION)
  • 8.4 BLOOD DISORDERS

The Division of Blood Diseases and Resources (DBDR), a part of the National Heart, Lung, and Blood Institute (NHLBI), supports research on blood diseases such as anemia, sickle cell disease (SCD), and thalassemia.

  • Biosimilar
  • Blood Disease
  • World
  • Market Size
  • Sandoz Inc.
  • Market challenges

These therapies have seen reluctance among the individuals due to the issue of developing inhibitors and further risk of blood-borne diseases.

  • Blood Disease
  • Forecast
  • Market Size
  • Biogen Idec Inc.
  • CSL Behring GmbH
  • M-009 - DRUG PROFILE
  • FEATURED NEWS & PRESS RELEASES

In beta-thalassemia, a long-studied genetic disorder, a mutation impairs hemoglobin production, resulting in defective red blood cells (RBCs).

  • Blood Disease
  • Pathology
  • Therapy
  • United States
  • Product Initiative
  • PIPELINE BY BELLICUM PHARMACEUTICALS INC, H2 2017

IT IS IN PHASE I/ II STAGE OF DEVELOPMENT FOR THE TREATMENT OF GRAFT VERSUS HOST DISEASE IN PATIENTS WITH LEUKEMIAS, LYMPHOMAS AND GENETIC BLOOD DISEASES.

  • Blood Disease
  • Chemotherapy
  • United States
  • World
  • Product Initiative
  • GLOBAL THERAPEUTIC APHERESIS MARKET SIZE, BY PROCEDURE, 2014-2021, (USD MILLION)

In this process, the patient' s blood is passed through a system to remove defective blood components/ cells or to remove disease-provoking elements from the blood.

  • Blood Disease
  • World
  • Market Size
  • Cerus Corporation
  • Fresenius Group

Fanconi anemia is a rare pediatric blood disease characterized by multiple physical abnormalities, bone marrow failure and a higher than normal risk of cancer.

  • Blood Disease
  • Therapy
  • United States
  • Company
  • Abeona Therapeutics, Inc.
  • National Heart Lung and Blood Institute, Key Employees
  • SEP 30, 2016: NHLBI AWARDS GRANTS TO HELP IMPROVE HEALTH OUTCOMES FOR TEENS, ADULTS WITH SICKLE CELL DISEASE

The institute conducts research studies with patients who have diseases of heart and blood vessels, lungs, blood cells and bone marrow, and cholesterol.

  • Blood Disease
  • HIV AIDS
  • Therapy
  • United States
  • GlobalData's company
  • SMALL MOLECULES TO INHIBIT PRMT5 FOR HAEMOGLOBINOPATHIES AND SOLID TUMOURS - DRUG PROFILE
  • M-009 - DRUG PROFILE

In addition, treatment with ACE-## corrected anemia in animal models of chronic kidney disease and acute blood loss.

  • Blood Disease
  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative
  • RECENT DEVELOPMENTS IN BLOOD DISORDERS BIOSIMILARS
  • GLOBAL - BLOOD DISORDERS BIOSIMILARS MARKET (MILLION US$), 2014 - 2015

Blood disorders can affect any of the three main components of blood: Red blood cells, which carry oxygen to the body' s tissues, White blood cells, which fight infections, Platelets, which help blood to clot.

  • Blood Disease
  • World
  • Market Size
  • Amgen Inc.
  • Biocon Limited
  • Fanconi Anemia - Drug Profiles
  • Blood Disease
  • United States
  • World
  • Product Initiative
  • Abeona Therapeutics, Inc.
  • AGGRAM - HIT TEST - PRODUCT DESCRIPTION
  • DIAGNOSTIC TEST - ARTERIAL THROMBOSIS - PRODUCT DESCRIPTION

With sickle cell disease, the misshapen red blood cells become hard and sticky, making it difficult for them to move through blood vessels.

  • Blood Disease
  • Clinical Trial
  • Diagnostics
  • Healthcare
  • GlobalData's company
  • SPINIT DEVICE - THROMBOCYTOPENIA ASSAY - PRODUCT DESCRIPTION

Biohit s sensitive and specific Celiac Disease Quick Test helps detect celiac disease patients among those with dyspeptic symptoms.

  • Blood Disease
  • Clinical Trial
  • Medical Device
  • Point Of Care Testing
  • GlobalData's company

Cord blood stem cells are mainly used for the treatment of diseases related to blood - diseases such as leukaemia, anemia, etc.

  • Blood Disease
  • Stem Cell
  • World
  • Market Size
  • Cordlife Group Limited
  • FEATURED NEWS & PRESS RELEASES

IN THIS DISEASE, THE BLOOD COAGULATION REACTION DOES NOT NORMALLY PROCEED BECAUSE OF CONGENITAL DEFICIENCY OF FACTOR VIII.

  • Blood Disease
  • Therapy
  • United States
  • World
  • Product Initiative
  • Global blood disorders biosimilars market

However, the inclusion of end-stage kidney disease (ESRD) in the list of major diseases by the Zaraxio is the first approved biosmilar in the US in 2015 for the treatment of blood-related diseases.

  • Blood Disease
  • Biocon Limited
  • Hospira, Inc.
  • Sandoz Inc.
  • Teva Pharmaceuticals Ltd.